- Home
- GALT vs PBYI Comparison
GALT vs PBYI Comparison
Compare GALT & PBYI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GALT
- PBYI
- Stock Information
- Founded
- GALT 2000
- PBYI 2010
- Country
- GALT United States
- PBYI United States
- Employees
- GALT N/A
- PBYI N/A
- Industry
- GALT Biotechnology: Pharmaceutical Preparations
- PBYI Biotechnology: Pharmaceutical Preparations
- Sector
- GALT Health Care
- PBYI Health Care
- Exchange
- GALT Nasdaq
- PBYI Nasdaq
- Market Cap
- GALT 147.8M
- PBYI 153.2M
- IPO Year
- GALT N/A
- PBYI N/A
- Fundamental
- Price
- GALT $2.12
- PBYI $2.92
- Analyst Decision
- GALT Strong Buy
- PBYI Strong Buy
- Analyst Count
- GALT 1
- PBYI 1
- Target Price
- GALT $11.00
- PBYI $7.00
- AVG Volume (30 Days)
- GALT 549.5K
- PBYI 416.5K
- Earning Date
- GALT 11-13-2024
- PBYI 11-07-2024
- Dividend Yield
- GALT N/A
- PBYI N/A
- EPS Growth
- GALT N/A
- PBYI 492.79
- EPS
- GALT N/A
- PBYI 0.47
- Revenue
- GALT N/A
- PBYI $243,569,000.00
- Revenue This Year
- GALT N/A
- PBYI N/A
- Revenue Next Year
- GALT N/A
- PBYI N/A
- P/E Ratio
- GALT N/A
- PBYI $6.26
- Revenue Growth
- GALT N/A
- PBYI 6.30
- 52 Week Low
- GALT $1.56
- PBYI $2.23
- 52 Week High
- GALT $4.27
- PBYI $7.73
- Technical
- Relative Strength Index (RSI)
- GALT 39.78
- PBYI 47.45
- Support Level
- GALT $1.80
- PBYI $2.82
- Resistance Level
- GALT $2.36
- PBYI $3.12
- Average True Range (ATR)
- GALT 0.23
- PBYI 0.20
- MACD
- GALT -0.03
- PBYI -0.03
- Stochastic Oscillator
- GALT 26.89
- PBYI 14.71
About GALT Galectin Therapeutics Inc.
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.
About PBYI Puma Biotechnology Inc
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes innovative products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis leading to apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.